Clinical Trial

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

Study acronym: CHAPTER-4
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema
Protocol Amendment History 1 change
notable Trial sites expanded: 24 -> 62 locations 2026-05-08
Trial Details
NCT Number NCT06679881
Lead Sponsor Pharvaris Netherlands B.V.
Conditions Hereditary Angioedema (HAE)
Enrollment 170 participants
Start Date 2025-02-01
Primary Completion 2028-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-07